Cover Image
市場調查報告書

RORγ調節因素:RORγ拮抗劑與促效劑狀況比較分析

RORgamma Modulators 2016: A Comparative Analysis of the Landscape of RORgamma Antagonists and Agonists

出版商 La Merie Publishing 商品編碼 351304
出版日期 內容資訊 英文 88 Pages
訂單完成後即時交付
價格
Back to Top
RORγ調節因素:RORγ拮抗劑與促效劑狀況比較分析 RORgamma Modulators 2016: A Comparative Analysis of the Landscape of RORgamma Antagonists and Agonists
出版日期: 2016年02月03日 內容資訊: 英文 88 Pages
簡介

維生素A酸相關孤核受體γ (RORγ) ,是引人注目的困難藥物標的。現在有30家公司以上,致力於藥物研發與開發。

對本報告以發炎性、自體免疫疾病的RORγ拮抗劑和對癌症治療的RORγ促效劑為主題,提供各種科學性理由相關驗證之系統性資訊。

第1章 簡介

第2章 摘要整理

第3章 標的背景

第4章 標的檢驗

  • Anti-IL17抗體的臨床性成功
  • 非臨床性的標的檢驗
  • 對RORγ拮抗劑的臨床性的主適應
  • 標的相關的潛在安全上的疑慮

第5章 藥物研發方法及技術

  • 藥物研發的共同研究
  • RORγ調節因素的藥物研發共同研究的商業性價值
  • 夥伴關係計劃的RORγ拮抗劑的藥物研發R&D時間軸
  • 核受體配體的藥物研發策略

第6章 RORγ調節因素的競爭情形

  • 對發炎性、自體免疫疾病的RORγ拮抗劑
  • 對癌症的RORγ促效劑

第7章 企業相關利益者

  • 非合作夥伴技術企業
  • 夥伴關係
  • 非合作夥伴製藥企業

第8章 參考資料

圖表

目錄
Product Code: LMFR0017

Retinoic acid-related orphan nuclear receptor gamma (RORgamma) is a hot, but "difficult-to-drug" target. More than 30 companies are active in drug discovery and development. Technology companies with expertise in discovery of drugs targeting nuclear hormone receptors are preferred partners of Big Pharma and Biotech companies if they have identified novel scaffolds of RORgamma antagonists. More than ten such technology-pharma partnerships have been founded and already lead to first successes. Three RORgamma antagonists (inverse agonists) are already in clinical development and more to follow in 2016 and thereafter.

The report explains the scientific rationale for discovering antagonists of RORgamma for treatment of autoimmune and inflammatory diseases, but also of agonists of RORgamma for treatment of cancer. Clinical as well as non-clinical data for target validation of RORgamma are provided. Lead and up-side indications for development including the key product profile are discussed. Potential safety concers for novel RORgamma modulators were identified. Drug discovery approaches of technology and pharmaceutical companies are shown regarding strategies in partnering as well as in technologies applied for structure-based drug discovery. Based on the experience in the past, estimates of the required time from start of a discovery program of RORgamma modulators until entry into human studies are calculated. The competitive landscape of RORgamma modulator development and discovery projects is analyzed and the profiles of companies elaborated, separately for unpartnered technology or pharmaceutical companies and for partnerships between technology and pharmaceutical companies.

The report provides an understanding of:

  • The target RORgamma
  • Clinical and non-clinical target validation
  • Clinical lead and up-side indications
  • Drug discovery strategies and technologies
  • Commercial value of drug discovery collaborations
  • R&D timelines from start of screening to first-in-human studies
  • Competitive landscape of RORgamma antagonists
  • Agonists of RORgamma for cancer
  • Profiles of unpartnered technology companies and lead projects
  • R&D Partnerships and their discovery approaches and lead molecules
  • Unpartnered pharmaceutical companies and their programs

Table of Contents

1) Introduction

2) Executive Summary

3) Target Background

4) Target validation

  • Clinical Success of Anti-IL17 Antibodies
  • Non-Clinical Target Validation
  • Clinical Lead Indication for RORgamma Antagonists
  • Target-related Potential Safety Concerns

5) Drug Discover Approaches & Technologies

  • Drug Discovery Collaboration
  • Commercial Value of RORgamma Modulator Drug Discovery Collaborations
  • R&D Timelines for Discovery of RORgamma Antagonists in Partnership Programs
  • Strategies for the Discovery of Nuclear Receptor Ligands

6) Competitive Landscape of RORgamma Modulators

  • RORgamma Antagonists for Inflammatory and Autoimmune Diseases
  • Agonists of RORgamma for Cancer

7) Corporate Stakeholders

  • Unpartnered Technology Companies
  • Partnerships
  • Unpartnered Pharmaceutical Companies

8) References

Tables in the report

  • Table 1: Disease Models Used for Non-Clinical Studies of RORgamma Antagonists
  • Table 2: Overview of Non-Clinical Studies of RORgamma Antagonists in Psoriasis Models
  • Table 3: Overview of Non-Clinical Studies of RORgamma Antagonists in Multiple Sclerosis Models
  • Table 4: Overview of Non-Clinical Studies of RORgamma Antagonists in Arthritis Models
  • Table 5: Overview of Non-Clinical Studies of RORgamma Antagonists in Inflammatory Bowel Disease and Ulcerative Colitis Models
  • Table 6: Overview of Non-Clinical Studies of RORgamma Antagonists in Systemic Lupus Erythematosus Models
  • Table 6: Overview of Partnership Agreements for RORgamma Modulators
  • Table 7: Special Collaborations for Discovery of RORgamma Antagonists
  • Table 8: Financial Terms of Partnership Agreements for RORgamma Modulators
  • Table 9: R&D Timeline for Discovery of RORgamma Antagonists in Partnership Programs
  • Table 10: Technologies for Discovery of RORgamma Antagonists
  • Table 11: RORgamma(T) Antagonists / Inverse Agonists in Clinical Development
  • Table 12: RORgamma(T) Antagonists / Inverse Agonists in pre-IND Studies
  • Table 13: RORgamma(T) Antagonists / Inverse Agonists in Preclinical R&D
  • Table 14: RORgamma(T) Antagonists / Inverse Agonists Discovery Programs
  • Table 15: RORgamma Agonists Discovery & Development Programs
  • Table 16: Technology and Pharma Companies with RORgamma Modulator R&D

Companies mentioned in the report

  • 4SC Discovery
  • Advinus Therapeutics
  • Amgen
  • Argenta
  • Arrien Pharmaceuticals
  • AstraZeneca
  • Aurigene Discovery Technologies
  • Biogen
  • Boehringer Ingelheim
  • Brickell Biotech
  • Bristol-Myers Squibb
  • Celgene
  • Daiichi Sankyo
  • Exelixis
  • Genfit
  • GlaxoSmithKline
  • Glenmark Pharmaceuticals
  • Innovimmune Biotherapeutics
  • Janssen Biotech
  • Japan Tobacco
  • Karo Bio
  • Lycera
  • Merck
  • Nuevolution
  • ORCA Pharmaceuticals
  • Orphagen Pharmaceuticals
  • Pfizer
  • Phenex Pharmaceuticals
  • Piramal (& Krish Biotech)
  • Roche
  • Takeda Pharmaceutical Co.
  • Teijin Pharma
  • Tempero Pharmaceuticals
  • Visionary Pharmaceuticals
  • Vitae Pharmaceuticals
Back to Top